November 15-16

Boston, MA

REGISTER HERE

 

Speakers

Expand/Collapse

Prof. Rob Knight
Department of Pediatrics
University of California San Diego

Rob Knight is a Professor in the Department of Pediatrics, with an additional appointment in the Department of Computer Science, at the University of California San Diego. He was chosen as one of 50 HHMI Early Career Scientists in 2009, is a Senior Editor at the ISME Journal, a member of the Steering Committee of the Earth Microbiome Project, and a co-founder of the American Gut Project.

Day One

Wednesday, November 15 2017

09.00 | The Microbiome, Nutrition and Human Biology

Chris Damman
MD, Program Officer
Bill and Melinda Gates Foundation

Dr. Damman is a board certified gastroenterologist with joint appointments at the Seattle Cancer Care Alliance and University of Washington Medical Center. His education and training include a B.A./M.A. from Wesleyan University in 1998/1999, an M.D from Columbia University in 2006, residency in internal medicine from the University of Washington in 2009, and fellowship in gastroenterology from the University of Washington in 2014.

Day One

Wednesday, November 15 2017

09.30 | More than a Crap Shoot…Placing Bets on Enteric Health for Healthy Growth & Development in the Developing World

Maciej Chichlowski
Principal Scientist, Global Discovery R&D
Mead Johnson Nutrition

Day Two

Thursday, November 16 2017

15.30 | Prebiotics Impact the Gut Microbiome and Brain of Developing Animals: Evidence for Effects on the Gut-Brain Axis

Paul Giannasca
Global Scientific Lead- GI Health
Nestle Health Science

As Global Scientific Lead - GI Health, Paul is responsible for developing R&D strategies as well as building and managing the GI Health pipeline, which leverages various nutritional and technological platforms. Paul has over 20 years of research and development experience in vaccines and infectious diseases and most recently served as VP of development at Genocea Biosciences. Previously, he was the Project Leader for the C. difficile vaccine program at Acambis and Sanofi Pasteur.  Paul received his PhD in Molecular and Cellular Biology from the University of Massachusetts-Amherst and completed post-doctoral training in mucosal immunology and enteric infections at Harvard Medical School.

Day One

Wednesday, November 15 2017

10.00 | Novel Nutritional Interventions for Human Health: Exploiting New Learnings in Gut Ecosystem Biology

Alan Murray
CEO
Next Foods/GoodBelly

CEO Alan Murray, has been involved with NextFoods from its inception, joining the company from a 30 year career with TetraPak, latterly as CEO of its North American business, and Unilever.

Day Two

Thursday, November 16 2017

13.00 | Probiotics: Communicating with the Consumer, from Clinical to Quirky

Mark Braman
President & CEO
Pantheryx

Mark has more than 30 years of experience in the nutrition and life science industries. He brings strong leadership and extensive expertise in areas key to PanTheryx, Inc., including business start-up and growth through licensing, mergers and acquisitions, external partnering, raising venture capital, and preparing and staging IPOs, and successfully launching new products domestically and internationally. He currently serves as a Board Director for Hidden Villa Ranch, Inc., and is Chairman of the Board for Third Wave Beverages, Inc. Previously, Mr. Braman was president and CEO for Efficas, Inc., purchased in 2010 by Luberski Holdings, Inc, where he directed the start-up of the company and successfully licensed and developed medical food products. Senior executive leadership roles were held with Pfizer Inc., Cultor Food Science, Inc, Cultor LTD a $1.4BB company; and OmegaTech, Inc., which he successfully sold to Martek Biosciences in 2002. Mr. Braman completed both a BA and executive management studies at the University of Michigan.

Day Two

Thursday, November 16 2017

09.00 | A Gut Punch to Traditional Healthcare: How Nutrition-Based Solutions Will Change How We Address Diseases

Lihi Segal
CEO
DayTwo

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo. For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Day One

Wednesday, November 15 2017

14.30 | Machine Learning in the Microbiome: Providing Predictable Personalized Nutrition based on Your Gut

Maile Combs
Senior Nutrition Scientist
The Nature's Bounty Co.

Day Two

Thursday, November 16 2017

14.30 | Panel Discussion: Formulating with Probiotics: Selecting Strains for Stability and Validity

Prof. Johanna Lampe
Department of Epidemiology
University of Washington

Johanna Lampe, PhD, RD, is a Full Member in the Public Health Sciences Division at Fred Hutchinson Cancer Research Center and a Research Professor in the Department of Epidemiology at the University of Washington in Seattle. The Lampe lab studies the effect of diet on gut microbial community and the relationship of the gut microbiome to biomarkers of cancer risk and routinely measures isoflavones, lignans, and other biomarkers of plant-food intake for population-based studies.

Day One

Wednesday, November 15 2017

13.00 | Gut Microbial Metabolism of Dietary Constituents: Whose Diet Is It Anyway?

Marcia Monaco
Research Assistant Professor, Food Science and Human Nutrition
University of Illinois

Day One

Wednesday, November 15 2017

16.00 | Non-invasive Methods for Assessing Nutritional Regulation of Neonatal Gut Gene Expression and Host-Microbe Interactions in the Human Infant

Anita Wichmann
Senior Scientist
Chr. Hansen

Day Two

Thursday, November 16 2017

10.00 | How New Insights in Mode of Action Fuel Probiotic Research

Shahram Lavasani
Founder & CEO
ImmuneBiotech

Shahram Lavasani holds a PhD degree from Lund University (Sweden), in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS). He is a skillful immunologist with many years of research expertise on gastrointestinal complications in chronic inflammatory diseases. Focusing on the Gut-Brain Axis he has pioneered research in MS by demonstrating increased intestinal permeability and design of therapies targeting the gut microbiota. He is the founder of ImmuneBiotech, developed a proprietary lactobacilli library and established careful and multiple selection methods to screen and design formulations for the optimal therapeutic management of the diseases.

Day One

Wednesday, November 15 2017

10.30 | Designed Microbiome Therapies Targeting the Microbes and Beyond

David Kyle
CEO
Evolve BioSystems

Dr. David Kyle is the CEO of Evolve Biosystems Inc., a spin-off of the University of California at Davis.  He founded several companies during his career, including Martek Biosciences where he led R&D and BD, and whose DHA and ARA products are now found in virtually all infant formulas around the world. Dr. Kyle has published over 80 scientific articles and is the named inventor on over 150 patents worldwide.  In 2009 Dr. Kyle was inducted into the US Space Technology Hall of Fame for his contributions to Science and Industry.

Day One

Wednesday, November 15 2017

15.00 | From Dysbiosis to Recovery in the Infant Gut Microbiome: A New Paradigm in Infant Nutrition

Solange Henoud
Director, Regulatory Affairs
Lallemand

Solange joined Lallemand in 2007. She leads regulatory affairs at the global level, actively represents the company in trade associations and is chair of the regulatory affairs committee at the International Probiotics Association (IPA). Solange has been involved in many successful company and industry initiatives advocating probiotics to Health Canada, the US Food and Drug Administration, the Brazilian Agência Nacional de Vigilância Sanitària and currently trying with the European and other authorities over the world. The achievement she is mostly proud of is the Canadian approval of health claims specific to Lallemand products in various indications. She entered the regulatory affairs arena after immigration to Canada from her native Lebanon where she studied science then architecture and ran her own practice.

Day Two

Thursday, November 16 2017

12.30 | Aligning Regulation, Science and Industry For a Clear Path to Market

Patrick Veiga
Head of the Microbes and Foods for Health Team
Danone Nutricia Research

Day One

Wednesday, November 15 2017

12.00 | Rethinking Diet to Aid Human–Microbe Symbiosis

Niklas Larsson
Research Director
Probi

Niklas has a BSc and a PhD in analytical chemistry from Lund University, Sweden. He has a background within the medical device industry in Denmark and has spent 3 years at Novo Nordisk A/S as a research scientist and an additional 3 years as R&D Director at Millimed A/S, a venture-funded company. In May 2008 Niklas joined Probi AB as research director, responsible for clinical research, patenting and regulatory questions. He currently coordinates and manages several probiotic related research projects with special focus on clinical trial design in relation to regulatory demands. Since joining Probi Niklas has been responsible for the execution of several clinical trials, collaborations with both academia and industry partners, health claim applications on various markets as well as patent applications. Today his responsibilities also includes scientific sales and customer support.

Day Two

Thursday, November 16 2017

14.30 | Panel Discussion: Formulating with Probiotics: Selecting Strains for Stability and Validity

Angela Horvath
Postdoctoral Researcher
University of Graz

After her master’s degree in Biology/Anthropology at the University of Vienna she pursued her PhD in Molecular Fundamentals of Inflammation at the Medical University of Graz where she currently works as a postdoctoral researcher. Her field of research is the influence of probiotics on gut permeability and innate immune responses in cirrhosis.

Day Two

Thursday, November 16 2017

15.00 | Food for Thought: The Emerging Role of Nutrition in the Microbiota-Gut–Brain Axis

Arland Hotchkiss
Lead Scientist
U.S. Deparment of Agriculture

Arland T. Hotchkiss, Jr. is Lead Scientist in the Dairy and Functional Foods Research Unit at the Eastern Regional Research Center, United States Department of Agriculture, Agricultural Research Service in Wyndmoor, Pennsylvania, USA. He is also an Adjunct Graduate Faculty Member at Rutgers University, Department of Food Science, New Brunswick, NJ, USA and served as the Otto Mønsted-Guest Professor at the Technical University of Denmark, Department of Chemical and Biochemical Engineering. He leads a functional food research team that includes dairy lactic acid microbial biotechnology, prebiotic/probiotic bioactive food ingredients, novel prebiotics that also inhibit food-borne pathogen adhesion/invasion and play a role in immunomodulation. The author of highly cited journal articles and book chapters, he has served on Cellulose and Beneficial Microbes editorial boards. He has been recognized with several awards including the Melville L. Wolfrom Award from the American Chemical Society, Division of Carbohydrate Chemistry. His technology transfer includes research with the world’s largest fruit and vegetable fiber, pectin and modified citrus pectin food ingredient companies.

Day Two

Thursday, November 16 2017

11.00 | Dietary Fiber, Prebiotics and Anti-Adhesive Oligosaccharides

Sai Chaluvadi
EVP,R&D, Operations
Pure Steeps Beverage, LLC

Sai Chaluvadi is Executive VP at Pure Steeps Beverage, LLC where he is responsible for growing a portfolio of new age functional beverages. Sai leads a team of scientists working in the area of prebiotic, probiotic and fermented beverages focused on balancing the product characteristics with regulations and functionality. He is also a doctoral candidate at Rutgers University and a visiting scientist in Dairy and Functional Foods research unit at USDA-ARS. He has presented his research in prestigious forums such as IFT, NYAS, ACS, HMS along with contributions to journal articles and a book chapter. He is actively involved in media communications debating about the knowledge gaps and practices in the current kombucha market.

Day Two

Thursday, November 16 2017

11.30 | Probiotics: Gaps in Current Practices, and a Case for Postbiotics

Kiran Krishnan
Chief Scientific Officer
Microbiome Labs

Kiran Krishnan is a Research Microbiologist and has been involved in the dietary supplement and nutrition market for the past 16 years. He comes from a strict research background having spent several years with hands-on R&D in the fields of molecular medicine and microbiology at the University of Iowa. Mr. Krishnan earned his Bachelor of Science degrees in Microbiology at the University of Iowa; his undergraduate education was followed up with post graduate research in Molecular Biology and Virology. He left University research to take a position as the U.S. Business Development and Product Development lead for Amano Enzyme, USA. Amano is one of the world’s largest suppliers of therapeutic enzymes used in the dietary supplement and pharmaceutical industries in North America. Kiran also established a Clinical Research Organization where he designed and conducted over a dozen human clinical trials in human nutrition. Kiran is also a co-founder and partner in Nu Science Trading, LLC.; a nutritional technology development, research and marketing company in the U.S. Dietary Supplement and Medical Food markets. Most recently, Kiran is acting as the Chief Scientific Officer at Physician’s Exclusive, LLC. and Microbiome Labs. He is a frequent lecturer on the Human Microbiome at Medical and Nutrition Conferences. He conducts the popular monthly Microbiome Series Webinars through the Rebel Health Tribe Group practitioner training program, he has been invited as an expert guest on National Radio and Satellite radio and has been a guest speaker in several Health Summits as a microbiome expert. He is currently involved in 3 novel human clinical trials on probiotics and the human microbiome. Kiran offers his extensive knowledge and practical application of the latest science on the human microbiome as it relates to health and wellness.

Day Two

Thursday, November 16 2017

09.30 | The Role of Spore-Based Probiotics in Reducing Metabolic Endotoxemia and Associated Chronic Disease Risk

Mahmoud Ghannoum
Professor
Case Western Reserve Univerisity

Mahmoud Ghannoum, Ph.D., MBA, FIDSA, joined Case Western Reserve University and University Hospitals Cleveland Medical Center in 1996 from prior positions at the UCLA School of Medicine and Kuwait University. Dr. Ghannoum has spent his entire academic career studying medically important fungi encompassing different fungal pathogens including Candida, Aspergillus and Cryptococcus, the major causes of fungal infections. He published more than 250 peer-reviewed articles addressing various aspects of superficial and systemic fungal infections. Recently he published the first study describing the oral mycobiome of health individuals. He has published extensively in the area of fungal pathogenesis with special focus on virulence factors including phospholipase B, germination, adhesion, and biofilm formation, both in vitro and in vivo. Recently, Dr. Ghannoum has been involved in characterizing the oral microbiome in health and disease, specifically has pioneered characterization of the human mycobiome (the fungal component of the human microbiota that make up the normal flora in HIV patients). This research may identify relationships between fungal species and their effect on various human diseases. Dr. Ghannoum is a successful entrepreneur, having co-founded multiple companies that have raised millions of dollars and commercialized products.

Day Two

Thursday, November 16 2017

12.00 | The Unaddressed Role of Fungi in Probiotics as it relates to Overall Health and Wellness

Katherine Dunn
Research Associate
Dalhousie University

Dr Dunn is a Research Associate with the Center for Comparative Genomics and Evolutionary Bioinformatics (CGEB) and the Department of Biology at Dalhousie University in Halifax Canada.  CGEB is a cross-disciplinary group utilizing their expertise's to examine changes in microbial diversity and function.  Dr Dunn has co-authored a number of papers examining changes in the microbiome of Crohn’s disease patients during nutritional therapy and using Bayesian models to predict patient outcome.

Day One

Wednesday, November 15 2017

12.30 | Microbiome Community Structure and Prediction of Response to Nutritional Therapy in Pediatric Crohn's Disease

Michelle McGuire
Professor, Nutrition
Washington State University

Shelley McGuire received her BS in biology from the University of Illinois (1986), an MS in nutritional sciences from the University of Illinois (1988), and a PhD in human nutrition from Cornell University (1994). Her research focuses primarily on understanding better how maternal dietary intake and nutritional status influence breast health, milk composition, and duration of postpartum amenorrhea.

Day One

Wednesday, November 15 2017

16.45 | What's Normal? The Human Milk Microbiome - a Paradigm Shift in Infant Nutrition

Stefan Jennewein
CEO & Founder
Jennewein Biotech

Dr. Stefan Jennewein studied Biochemistry, Pharmacology and Organic Chemistry at the Universities of Sussex (Brighton, UK), Zurich (CH), Tübingen (D) and Cambridge (UK), and at the Ludwig-Maximilians-Universität (Munich, D). Dr. Stefan Jennewein also gained practical experience through his work at Washington State University (Pullman, USA), the company DSM N.V. (Delft, NL), the Technical University of Darmstadt (D), and the Fraunhofer Institute for Molecular Biology and Applied Ecology (Aachen, D). Dr. Stefan Jennewein is the Managing Director for research and development, regulatory issues, and quality management at Jennewein Biotechnologie.

Day One

Wednesday, November 15 2017

16.30 | Human Milk Oligosaccharides (HMOs) Nature’s Prebiotics for a Healthy Infant Microbiome